Relacorilant clinical trials
Relacorilant is named as an intervention in 5 current clinical trials in our USA, France, Spain, Italy, Poland, Belgium, Canada, South Korea, Israel, Germany, UK, Brazil, Australia, Netherlands and Austria registers. 2 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Corcept Therapeutics (4). The most-studied condition is Peritoneal Neoplasms.
Where Relacorilant is approved
All regulators →Of the three regulators tracked here, the first to approve Relacorilant was the US, on 25 Mar 2026.
- 3 EU orphan designations, most recently for treatment of ovarian cancer (25 Jul 2023, positive)
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
Relacorilant patents and exclusivity
Expiry tracker →Protections still running for marketed products containing Relacorilant, as listed by the regulators. Expired patents and exclusivities, and discontinued products, are not shown.
- 10 listed patents; the last listed expires 22 Dec 2041 (US 12152028).
- Latest patent on the drug substance itself: 24 May 2033 (US 11576907).
- Exclusivity NCE: New chemical entity, until 25 Mar 2031.
Reproduced from the FDA Orange Book and Purple Book (checked 8 Nov 2026) and the European Commission's Union Register of medicinal products (CC BY 4.0; the EU expiry date is calculated exactly as the Commission's register displays it). Listed patents and dates are as submitted to or published by the regulator and may not reflect litigation, invalidation, settlements, lapsed fees or later extensions. This is not legal advice or a freedom-to-operate opinion, and it does not say when a generic or biosimilar will launch.
How Relacorilant works
All drug targets →- Glucocorticoid receptor antagonist AntagonistTarget: NR3C1 nuclear receptor subfamily 3 group C member 1✓ In ChEMBL and the Guide to Pharmacology
- Cushing syndromePhase 3
- Impaired glucose tolerancePhase 3
- Adrenal gland hyperfunctionPhase 3
- Congenital adrenal hyperplasiaPhase 3
- Fallopian tube cancerPhase 3
- Hypertensive disorderPhase 3
- Malignant epithelial tumor of ovaryPhase 3
- Ovarian carcinomaPhase 3
- Pancreatic ductal adenocarcinomaPhase 3
- Primary peritoneal carcinomaPhase 3
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL4068611, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 13830, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Relacorilant
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Relacorilant
5 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Relacorilant
10 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Corcept Therapeutics | 4 |
| ARCAGY/ GINECO GROUP | 1 |
By country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Relacorilant trials
How many clinical trials are testing Relacorilant?
5 current trials in our USA, France, Spain, Italy, Poland, Belgium, Canada, South Korea, Israel, Germany, UK, Brazil, Australia, Netherlands and Austria registers name Relacorilant (also registered as CORT125134) as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are Relacorilant trials recruiting patients?
Yes. 2 of the 5 trials are recruiting: 2 with sites in USA, 1 with sites in France, 1 with sites in Spain, 1 with sites in Italy, 1 with sites in Poland, 1 with sites in Belgium, 1 with sites in South Korea and 1 with sites in Germany. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Relacorilant clinical trials?
Corcept Therapeutics (4) and ARCAGY/ GINECO GROUP (1). The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Relacorilant works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Relacorilant works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Relacorilant (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.